...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical neuropharmacology >Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: A 10-week randomized study
【24h】

Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: A 10-week randomized study

机译：双盲，安慰剂对照试验Risperidone Plus in自闭症儿童中的amantadine：一个10周的随机研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: This study aimed to investigate the effect of adding amantadine to risperidone for treatment of autism. METHODS: Forty outpatients aged 4 to12 years, who were diagnosed with autism spectrum disorders based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision criteria, wereassigned to this double-blind clinical trial. The subjects were divided randomly into 2 groups. One group received risperidone plus amantadine, and the other group received risperidone plus placebo. The dose of risperidone was titrated between 1 and 2.0 mg/d, and the dose of amantadine was 100 or 150 mg/d for patients less than 30 kg or more than 30 kg, respectively. The patients were assessed using the Aberrant Behavioral Checklist-Community (ABC-C) and adverse effects checklist as well as clinical global impression-improvement (CGI-I) at2 checkpoints of 5-week intervals after the baseline. Informed consentwas obtained from the parents of each participant. RESULTS: Among ABC-C subscales, Hyperactivity and Irritability showed significantly greater reduction in the amantadine group than the placebo group. There was no significant difference in adverse effects between the 2 groups. The CGI-I scores show significant improvement in the amantadine group compared to the placebo group. CONCLUSIONS: The present study suggests that amantadine may be a potential adjunctive treatment strategy for autism and it was generally well tolerated.
机译：目的：本研究旨在探讨加入甘草胺对血吸虫治疗自闭症的影响。方法：4至12岁的四十个外分，是根据精神障碍的诊断和统计手册，第四版，文本修订标准，对这种双盲临床试验进行了诊断和统计手册，诊断出自闭症谱系手册。将受试者随机分成2组。一组接受了Risperidone Plus Amantadine，另一组接受了Risperidone加安慰剂。滴度在1-2.0mg / d之间滴定滴度，分别为少于30千克或超过30千克的患者为10​​0或150mg / d。使用异常行为核对表 - 群落（ABC-C）和不良反应清单以及临床全球印象 - 改进（CGI-I）在基线后5周间隔的临床全球印象改善（CGI-I）的评估。知情同意从每个参与者的父母获得。结果：在ABC-C类别中，比ANDANDINE组的多动和烦扰性比安慰剂组显着降低。 2组之间的不良反应没有显着差异。与安慰剂组相比，CGI-I分数显示甘露出基团的显着改善。结论：本研究表明，Amantadine可能是自闭症潜在的辅助治疗策略，并且通常耐受良好。

著录项

  • 来源
    《Clinical neuropharmacology》 |2013年第6期|共6页
  • 作者

    MohammadiM.-R.; YadegariN.; HassanzadehE.; FarokhniaM.; YekehtazH.; MirshafieeO.; AkhondzadehS.;

  • 作者单位

    Psychiatric Research Center Roozbeh Hospital Tehran University of Medical Sciences South Kargar;

    Psychiatric Research Center Roozbeh Hospital Tehran University of Medical Sciences South Kargar;

    Psychiatric Research Center Roozbeh Hospital Tehran University of Medical Sciences South Kargar;

    Psychiatric Research Center Roozbeh Hospital Tehran University of Medical Sciences South Kargar;

    Psychiatric Research Center Roozbeh Hospital Tehran University of Medical Sciences South Kargar;

    Psychiatric Research Center Roozbeh Hospital Tehran University of Medical Sciences South Kargar;

    Psychiatric Research Center Roozbeh Hospital Tehran University of Medical Sciences South Kargar;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药理学;
  • 关键词

    amantadine; autism; glutamate; randomized controlled trial; risperidone;

    机译：Amantadine;自闭症;谷氨酸;随机对照试验;risperidone;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号